Northwire Canada EditionSaturday, July 18, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 107
  1. Nov 06, 2025 · 07:30 · GUD

    Knight Therapeutics Reports Third Quarter 2025 Results

    Knight Therapeutics Reports Third Quarter 2025 Results

    01
  2. Nov 06, 2025 · 07:04 · AGN

    Algernon Health Announces Private Placement

    Algernon Health Announces Private Placement

    02
  3. Nov 06, 2025 · 07:01 · WELL

    WELL Health Reports Record Revenue, Record Adjusted EBITDA, and Record Adjusted Net Income in Q3-2025 Driven by Strong Performance in Core Canadian Businesses

    WELL Health Reports Record Revenue, Record Adjusted EBITDA, and Record Adjusted Net Income in Q3-2025 Driven by Strong Performance in Core Canadian Businesses

    03
  4. Nov 06, 2025 · 07:00 · MDNA

    Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma

    Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma

    04
  5. Nov 06, 2025 · 07:00 · DR

    Medical Facilities Corporation Announces Third Quarter Results

    Medical Facilities Corporation Announces Third Quarter Results

    05
  6. Nov 06, 2025 · 06:30 · DRUG

    Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

    Bright Minds Biosciences Initiates New Prader-Willi Syndrome (PWS) Program; KOL Event Scheduled for November 6TH

    06
  7. Nov 06, 2025 · 04:06 · SURE

    Surenano arranges $1.25-million private placement

    Surenano arranges $1.25-million private placement

    07
  8. Nov 06, 2025 · 03:16 · DTC

    Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

    Defence Announces Successful Presentation at the World ADC Conference in San Diego and Plans to Expand Evaluation of Accum in Commercial and Pipeline ADCs

    08
  9. Nov 05, 2025 · 19:51 · PCRX

    Pharmacorp Rx arranges $15-million financing

    Pharmacorp Rx arranges $15-million financing

    09
  10. Nov 05, 2025 · 18:37 · SURE

    SureNano Announces Private Placement

    SureNano Announces Private Placement

    10
  11. Nov 05, 2025 · 17:38 · OTC

    Ocumetics Lens shows early vision gains in trials

    Ocumetics Lens shows early vision gains in trials

    11
  12. Nov 05, 2025 · 17:00 · DHT

    DRI Healthcare Reports Third Quarter 2025 Results

    DRI Healthcare Reports Third Quarter 2025 Results

    12
  13. Nov 05, 2025 · 16:26 · PCRX

    PharmaCorp Announces C$15 Million Bought Deal Public Offering

    PharmaCorp Announces C$15 Million Bought Deal Public Offering

    13
  14. Nov 05, 2025 · 16:21 · CRDL

    Cardiol's Archer data to be presented Nov. 29

    Cardiol's Archer data to be presented Nov. 29

    14
← Newer Older →